ALZHEIMER'S DISEASE AND ITS TRADITIONAL TREATMENTS, AS WELL AS NEW TREATMENTS UNDER RESEARCH
Keywords:
ингибитор холинэстеразы, ингибитор холинэстеразымемантин, донепезил, рецептор NMDA, современные исследования методов лечения, NAD⁺, P7C3-A20Abstract
This article covers general and modern scientific views on Alzheimer's disease. In particular, the history, causes of the disease and mechanisms of pathogenesis are analyzed. The mechanisms of action of the main drugs currently used in the treatment of Alzheimer's disease, including cholinesterase inhibitors and NMDA receptor antagonists, are also reviewed. In addition, the article discusses, along with traditional treatment methods aimed at slowing down the disease, new scientific studies aimed at treating Alzheimer's disease, in particular, modern approaches related to the energy balance of brain cells and the NAD⁺ molecule. These studies may reveal the possibilities of not only slowing down the disease in the future, but also reversing its progression. The article aims to provide a deeper understanding of Alzheimer's disease and shed light on promising areas of its treatment.
References
Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift für Psychiatrie. 1907;64:146–148.
Khann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R. et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the NIA-AA workgroups. Alzheimer’s & Dementia. 2011;7(3):263–269.
Selkoe D.J., Hardy J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems. EMBO Molecular Medicine. 2016;8(6):595–608.
Cummings J., Lee G., Zhong K., Fonseca J., Taghva K. Alzheimer’s disease drug development pipeline: 2023. Alzheimer’s & Dementia. 2023;19(6):2243–2255.
Parsons C.G., Stöffler A., Danysz W. Memantine: A NMDA receptor antagonist for the treatment of Alzheimer’s disease. Neuropharmacology. 2007;53(6):699–723.
Rogers S.L., Doody R.S., Mohs R.C., Friedhoff L.T. Donepezil improves cognition and global function in Alzheimer’s disease. Neurology. 1998;50(1):136–145.
Longo V.D., Mattson M.P. Fasting, energy metabolism, and Alzheimer’s disease. Cell Metabolism. 2014;20(4):523–534.
Katsyuba E., Auwerx J. Modulating NAD⁺ metabolism, from bench to bedside. Cell Metabolism. 2017;26(3):529–547.
Pieper A.A., Xie S., Capota E. et al. Discovery of a proneurogenic, neuroprotective chemical. Cell. 2010;142(1):39–51.
Ibodullayev Z.R. Umumiy nevrologiya. Toshkent: Zamin Nashr; 2021.